# Perifosine + Sunitinib Malate for Patients With Advanced Cancers

> **NCT00399152** · PHASE1 · COMPLETED · sponsor: **AEterna Zentaris** · enrollment: 15 (actual)

## Conditions studied

- Renal Cancer
- GIST

## Interventions

- **DRUG:** Perifosine
- **DRUG:** Sunitinib Malate

## Key facts

- **NCT ID:** NCT00399152
- **Lead sponsor:** AEterna Zentaris
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-12
- **Final completion:** 2009-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2014-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00399152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00399152, "Perifosine + Sunitinib Malate for Patients With Advanced Cancers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00399152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*